Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017

Actelion Pharmaceuticals Ltd / Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017 . Verarbeitet und übermittelt durch Nasdaq Corporate Solutions. Für den Inhalt der Mitteilung ist der Emittent verantwortlich. Source: Globenewswire

ALLSCHWIL/BASEL, SWITZERLAND - October 31, 2017 - By decision dated October 25, 2017, the Cantonal Court of the Canton of Basel-Landschaft cancelled all publicly held registered shares of Actelion Ltd (Actelion) with a nominal value of CHF 0.50 each (the Actelion Shares) based on article 137 of the Federal Act on Financial Market Infrastructures and Market Conduct in Securities and Derivatives Trading (Financial Market Infrastructure Act).

The holders of the cancelled Actelion Shares will be paid a cash compensation in the amount of USD 280 for each cancelled Actelion Share, corresponding to the offer price paid by Janssen Holding GmbH, an indirect subsidiary of Johnson & Johnson, in its public tender offer for all publicly held Actelion Shares. The settlement and payment of the compensation to the remaining minority shareholders of Actelion will take place on or around November 10, 2017.

By decision dated April 18, 2017, SIX Exchange Regulation approved the delisting of the Actelion Shares from SIX Swiss Exchange. By decision dated October 30, 2017, SIX Exchange Regulation determined that the last day of trading of the Actelion Shares will be November 6, 2017 and that the Actelion Shares will be delisted from SIX Swiss Exchange on November 7, 2017.

###

NOTES TO EDITORS

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 130,800 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenUS and www.twitter.com/JanssenGlobal.

About Actelion Ltd

In June 2017, Actelion became part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Actelion's medicines help expand and strengthen Janssen's portfolio with leading, differentiated in-market medicines and promising late-stage compounds. Janssen has added Pulmonary Hypertension as a therapeutic area of focus to maintain the leadership position Actelion has built in this important disease area.

For further information please contact:
Investor Relations - Actelion Pharmaceuticals Ltd
+41 61 565 6565
www.actelion.com

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the acquisition of Actelion Ltd. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks and uncertainties related to the ability of the Johnson & Johnson family of companies to successfully integrate the products, employees/operations and clinical work of Actelion, as well as the ability to ensure continued performance or market growth of Actelion's products; the potential that the expected benefits and opportunities of the transaction may not be realized or may take longer to realize than expected; challenges inherent in product research and development, including the uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; competition, including technological advances, new products and patents attained by competitors; adverse litigation or government action; challenges to patents; changes to applicable laws and regulations, including domestic and foreign health care reforms; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors and the general risks associated with the respective businesses of Johnson & Johnson and Actelion can be found in Johnson & Johnson's publicly available filings with the U.S. Securities and Exchange Commission, and Actelion's publicly available filings on its website. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com, www.actelion.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

--- Ende der Mitteilung ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Schweiz

ISIN: CH0010532478;